New cardiovascular drug reduces oxidized phospholipids

Lepodisiran is a drug in clinical trials which reduces Lp(a), the strongest hereditary risk factor for heart disease.

This study analyzed the trial results and found it also reduced oxidized lipids, namely oxidized apoB. These are LDL cholesterol particles which are believed to be especially harmful.